Low-certainty evidence suggests that off-label fluoxetine may decrease weight compared with placebo .
However , low-certainty evidence suggests an increase in the risk for dizziness , drowsiness , fatigue , insomnia and nausea following fluoxetine treatment
BACKGROUND Fluoxetine is a serotonin reuptake inhibitor indicated for major depression .
It is also thought to affect weight control : this seems to happen through appetite changes result ing in decreased food intake and normalisation of unusual eating behaviours .
However , the benefit-risk ratio of this off-label medication is unclear .
OBJECTIVES To assess the effects of fluoxetine for overweight or obese adults .
Double-blind placebo-controlled trial of fluoxetine in smoking cessation treatment including nicotine patch and cognitive-behavioral group therapy.
Smoking cessation attempts are often complicated by dysphoria/depression , weight gain , craving , and other nicotine withdrawal symptoms . Fluoxetine 's antidepressant and anorectant properties , along with its capacity to attenuate compulsive behavior , suggest that this medication might facilitate smoking cessation treatment . We examined the effect of fluoxetine on smoking cessation in the context of a program that included group cognitive-behavioral therapy ( six weeks ) and transdermal nicotine patch(ten weeks ) . In a double-blind r and omized trial of fluoxetine for smoking cessation , 150 daily smokers were assigned to placebo ( n=48 ) , 20 mg ( n=51 ) , or 40 mg fluoxetine ( n=51 ) . Fluoxetine did not significantly improve smoking cessation rates , either for those with or without major depressive disorder(MDD)histories or elevated current depression . Our results suggest that fluoxetine may moderate withdrawal symptoms , even if that was not manifested in improved smoking cessation rates . Our results , however , clearly favor the use of fluoxetine if weight gain is a major clinical obstacle to smoking cessation
Low-certainty evidence suggests that off-label fluoxetine may decrease weight compared with placebo .
However , low-certainty evidence suggests an increase in the risk for dizziness , drowsiness , fatigue , insomnia and nausea following fluoxetine treatment
BACKGROUND Fluoxetine is a serotonin reuptake inhibitor indicated for major depression .
It is also thought to affect weight control : this seems to happen through appetite changes result ing in decreased food intake and normalisation of unusual eating behaviours .
However , the benefit-risk ratio of this off-label medication is unclear .
OBJECTIVES To assess the effects of fluoxetine for overweight or obese adults .